Procalcitonin in critically ill patients: Time to change guidelines and antibiotic use in practice

The Lancet Infectious Diseases

Volumn 16, Issue 7, 2016, Pages 758-760

  Schuetz, Philipp ^a   Müeller, Beat ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; PROTEIN PRECURSOR;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENT; DISEASE SEVERITY; HUMAN; INTENSIVE CARE UNIT; MORTALITY; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REINFECTION; RELAPSE; RESPIRATORY TRACT INFECTION; RISK REDUCTION; SURVIVAL; CRITICAL ILLNESS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOMARKERS; CALCITONIN; CALCITONIN GENE-RELATED PEPTIDE; CRITICAL ILLNESS; HUMANS; PROTEIN PRECURSORS;

EID: 84961231190     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)00064-5     Document Type: Note

References (15)

1. Schuetz P, Christ-Crain M, Muller B Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections-hope for hype?. Swiss Med Weekly 2009, 139:318-326.
2. Schuetz P, Aujesky D, Müller C, Müller B Biomarker-guided personalised emergency medicine for all-hope for another hype?. Swiss Med Weekly 2015, 145:w14079.
3. Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Müller B Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 2004, 32:1715-1721.
4. Laukemann S, Kasper N, Kulkarni P, et al. Can we reduce negative blood cultures with clinical scores and blood markers? Results from an observational cohort study. Medicine (Baltimore) 22015; 94: e2264.
5. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B Procalcitonin-Guided Antibiotic Therapy and Hospitalisation in Patients with Lower Respiratory Tract Infections (ProHOSP) Study Group. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 2011, 37:384-392.
6. Schuetz P, Maurer P, Punjabi V, Desai A, Amin DN, Gluck E Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Critical Care 2013, 17:R115.
7. Schuetz P, Chiappa V, Briel M, Greenwald JL Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011, 171:1322-1331.
8. Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012, 55:651-662.
9. Schuetz P, Mueller B Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes. Intensive Care Med 2014, 40:141.
10. Bouadma L, Luyt C-E, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474. for the PRORATA trial group.
11. Jensen J-U, Lundgren B, Hein L, et al. The Procalcitonin And Survival Study (PASS)-a randomised multi-center trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. BMC infectious diseases 2008, 8:91.
12. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39:165-228.
13. de Jong E, van Oeers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 2016, published online Feb 29. http://dx.doi.org/10.1016/S1473-3099(16)00053-0.
14. Mitsuma SF, Mansour MK, Dekker JP, et al. Promising new assays and technologies for the diagnosis and management of infectious diseases. Clin Infect Dis 2013, 56:996-1002.
15. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013, 13:426-435.